Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting

Phase 3 clinical trial to evaluate rimegepant as a preventive therapy for migraine expected to begin by the fourth quarter of 2018 Late-breaking oral presentation at AHS to present pivotal Phase 3 trial data showing single-dose rimegepant provides rapid... Biopharmaceuticals Biohaven Pharmaceutical, rimegepant, migraine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news